Description
Erbitux 500 MG cetuximab, in combination with radiation therapy, is a monoclonal antibody indicated for the initial treatment of locally or regionally advanced head and neck cancer of a specific type (squamous cell carcinoma).
Erbitux cetuximab is also approved to treat patients with head and neck cancers that have returned in the same location or spread to other parts of the body and for head and neck cancers that have progressed following platinum-based chemotherapy.
Erbitux Cetuximab is also used on metastatic colorectal cancers that contain epidermal growth factor receptors.
